Immunology and Pathology

Glomerular Expression of Dystroglycans Is Reduced in Minimal Change Nephrosis But Not in Focal Segmental Glomerulosclerosis

HEINRICH M. REGELE, EDITH FILLIPOVIC, BRIGITTE LANGER, HELGA POCZEWKI, ILSE KRAXBERGER, REGINALD E. BITTNER and DONTSCHO KERJASCHKI
JASN March 2000, 11 (3) 403-412;

Abstract

Abstract. Extensive flattening of podocyte foot processes and increased permeability of the glomerular capillary filter are the major pathologic features of minimal change nephrosis (MCN) and focal segmental glomerulosclerosis (FSGS). Adhesion proteins anchor and stabilize podocytes on the glomerular basement membrane (GBM), and presumably are involved in the pathogenesis of foot process flattening. Thus far, α3 β1-integrin was localized to basal cell membrane domains. In this report, α- and β-dystroglycan (DG) were detected at precisely the same location by immunoelectron microscopy, and the presence of α- and β-DG chains was confirmed by immunoblotting on isolated human glomeruli. Because the major DG binding partners in the GBM (laminin, agrin, perlecan), and the intracellular dystrophin analogue utrophin are also present in glomeruli, it appears that podocytes adhere to the GBM via DG complexes, similar to muscle fibers in which actin is linked via dystrophin and DG to the extracellular matrix. As with muscle cells, it is therefore plausible that podocytes use precisely actin-guided DG complexes at their “soles” to actively govern the topography of GBM matrix proteins. Expression of the α/β-DG complex was reported to be reduced in muscular dystrophies, and therefore a search for similar pathologic alterations in archival kidney biopsies from patients with MCN (n = 16) and FSGS (n = 8) was conducted by quantitative immunoelectron microscopy. The density of α-DG on the podocyte's soles was significantly reduced to 25% in MCN, whereas it was not different in normal kidneys and FSGS. The expression of β-DG was reduced to >50% in MCN, and was slightly increased in FSGS. Levels of DG expression returned to normal in MCN after steroid treatment (n = 4). Expression of β1-integrin remained at normal levels in all conditions. These findings point to different potentially pathogenic mechanisms of foot process flattening in MCN and FSGS.

Adhesion of podocytes to the glomerular basement membrane (GBM) is critically associated with the correct filter characteristics of the glomerular capillary wall, as supported by the finding that proteinuria is invariably associated with flattening of foot processes and occasionally also detachment of podocytes (1,2). The primary glomerular filter was localized to the GBM (3), and presumably is maintained by fibrillar and charged GBM matrix proteins arranged in a complex threedimensional pattern. It is not known, however, whether correct alignment of matrix components is achieved by self assembly (4), or actively regulated by podocytes. Because the basal cell membrane domain of foot processes is directly attached to the GBM, it is of some interest to map and understand molecular interactions between matrix proteins and appropriate podocyte cell membrane receptors. Thus far, only two types of adhesion proteins have been localized unambiguously by immunoelectron microscopy, i.e., α3 β1-integrin (5,6) and a transmembrane heparan sulfate proteoglycan of the syndecan family (7), and there is indirect evidence that α3 β1-integrin is involved in the stabilization of foot processes (8,9).

In this study, we define the glomerular localization of yet another class of adhesion proteins, the α- and β-dystroglycans (DG), which form transmembrane complexes in muscle and several nonmuscle cells (10,11). DG was previously observed in a GBM pattern by immunofluorescence (12,11). Here we have precisely localized α- and β-DG subunits by immunoelectron microscopy to the basal cell membrane domain of foot processes. In addition, we provide evidence that podocytes contain utrophin, a major intracellular binding partner of β-DG, by indirect immunofluorescence. To detect potential alterations of DG expression under pathologic conditions, we have examined its distribution in archival human kidney biopsies of minimal change nephrosis (MCN) before and after steroid treatment, and of segmental focal glomerular sclerosis (FSGS), and we have compared it with α3 β1-integrin. MCN and FSGS were chosen because the primary defect in these diseases is thought to reside in podocytes, and causes extensive flattening of foot processes and nephrotic-range proteinuria.

Materials and Methods

Patients and Renal Biopsies

Indirect immunohistochemistry was performed on paraffin sections of archival renal biopsies of 16 cases of clinically and morphologically typical MCN (five children, ages 2 to 11, and 11 adults, ages 24 to 67), and eight cases of FSGS (Table 1) that were clinically classified as idiopathic. All patients selected showed nephrotic-range proteinuria, and normal or only slightly elevated levels of serum creatinine (Table 1). Routine electron microscopy was used in all cases to monitor foot process morphology. MCN was diagnosed by the standard criteria (13) of extensive foot process flattening, in the absence of other pathologic glomerular changes, and nephrotic-range proteinuria without impairment of renal function. Four cases of MCN biopsies taken before and after successful steroid treatment were examined (Table 2). In biopsies from eight patients, FSGS was defined by typical segmental glomerular obsolescence, adhesion of the glomerular tuft to Bowman's capsule, extensive foot process flattening by electron microscopy, and nephrotic-range proteinuria. As controls, four samples with normal glomerular morphology from tumor nephrectomies were used.

View this table:
Table 1.

Visual estimate of the labeling intensity of glomeruli immunostained for α- and β-dystroglycan, and β1-integrina

View this table:
Table 2.

Estimate of the labeling intensity of glomeruli immunostained for α-dystroglycan of patients with minimal change nephrosis, before and after clinically successful steroid therapya

Antibodies

Mouse monoclonal IgG specific for the C-terminal 16 amino acids of human β-DG, anti-utrophin antibody (raised against a recombinant N-terminal 261 amino acid peptide), and monoclonal anti-human dystrophin IgG were obtained from Novocastra Laboratories (Newcastle, United Kingdom). Monoclonal IgG against rabbit α-DG was from Upstate Biotechnology (Lake Placid, NY), and against human β1-integrin from Transduction Laboratories (Lexington, KY), and provided by Dr. Robert Pytela (Lung Research Center, UCSF, San Francisco, CA). Affinity-purified rabbit anti-mouse IgG was from Dako (Copenhagen, Denmark), and sheep anti-rabbit IgG 10 nM immunogold conjugate was from Amersham (Amersham, United Kingdom).

Immunoblotting

Glomeruli were isolated from renal cancer nephrectomy specimens by graded sieving, lysed in sodium dodecyl sulfate sample buffer, electrophoresed on 10% gels, and transferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Human skeletal muscle was removed from laryngectomy specimens and was directly dissolved in sodium dodecyl sulfate sample buffer. Immunoblotting was performed with anti-α- or β-DG antibodies (5 to 10 μg IgG/ml), and detection was carried out with an enhanced chemiluminescence kit (Bio-Rad, Richmond, CA).

Immunohistochemistry

Two-micrometer-thick paraffin sections of archival kidney biopsies were dewaxed, rehydrated, micowaved (600 W, 10 min), and processed for indirect immunohistochemistry, as described (14). As secondary reagent, a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) was used. In control experiments, incubation with the primary antibodies was omitted, or they were replaced by irrelevant IgG of the same subclasses. Utrophin was localized in unfixed cryostat sections of normal human kidney by indirect immunofluorescence.

Labeling intensity of α- and β-DG- and β1-integrin-labeled sections of kidney biopsies was estimated by two independent reviewers, using normal controls and the labeling intensity of tubular basement membranes in the same sections as relative standards. At least six glomeruli per biopsy were evaluated at low-power magnification to assess the labeling intensity of whole glomeruli only and disregarding focal intraglomerular variations. The reviewer's scores were averaged and expressed from +++ to 0.

Immunoelectron Microscopy

Immunogold electron microscopy was performed on ultrathin frozen sections of kidney biopsies from patients with MCN and FSGS, as well as from healthy control subjects. Briefly, pieces of biopsies were fixed in 4% freshly prepared formaldehyde (by depolymerization of paraformaldehyde), 0.1% distilled glutaraldehyde (Merck, Darmstadt, Germany) in 100 mM phosphate buffer, pH 7.2, for 6 to 12 h at 4°C, soaked in sucrose, and frozen and stored in liquid nitrogen. Ultrathin frozen sections were processed for indirect immunogold labeling, as described (15). Alternatively, biopsies were embedded in Lowicryl K4M resin, and ultrathin sections were labeled by an indirect immungold protocol (16). In control experiments, incubation with primary antibodies was omitted, or they were replaced by irrelevant IgG of the same subclasses.

Quantitative Immunoelectron Microscopy

The number of gold particles per micrometer of basal cell membrane was determined on electron micrographs of Lowicryl K4M sections that permit evaluation of relatively large glomerular segments (15). Cell membranes from at least two glomeruli of three different patients in each group were evaluated. The results for α- and β-DG were based on the evaluation of the following total membrane lengths: 2046 and 3784 μm in control subjects, 1643 and 3770 μm in MCN, 2937 and 4849 μm in FSGS; for β1-integrin, the lengths were: 2553 μm in control subjects, 684 μm in MCN, and 1651 μm in FSGS.

Statistical Analyses

The mean values were calculated, and SD and significances were determined by unpaired t test. A P value <0.05 was regarded as statistically significant.

Results

Dystroglycans and β1-Integrin Localization in Normal Human Kidneys

In normal kidney, α- and β-DG are coexpressed in glomerular peripheral capillary loops in a GBM-like pattern (Figure 1, A and B), as reported previously (11,12). Proximal tubules and vascular smooth muscle cells also expressed both DG. Immunostaining with anti-β1-integrin IgG resulted in a similar labeling pattern, with the addition of mesangial reactivity (Figure 1 C). Interstitial blood vessels were stained similar to DG. In control experiments, the anti-DG antibodies outlined the basal membranes of skeletal muscle fibers (data not shown).

Figure 1.
Figure 1.

Gallery of glomeruli of normal kidneys (A through C), with focal segmental glomerulosclerosis (FSGS; D through F), and minimal change nephrosis (MCN; G through I). The paraffin sections of kidney biopsies were immunostained with anti-α-dystroglycan antibody (A, D, and G), β-dystroglycan (B, E, and H), or β1-integrin (C, F, and I). There is strong immunoreactivity of glomerular capillary loops in a glomerular basement membrane (GBM)-like pattern with all antibodies in normal kidneys and in FSGS. By contrast, only β1-integrin is preserved in MCN, while α- and β-dystroglycan are markedly reduced. This is particularly apparent when the relative difference between glomerular capillary loop staining and immunolabeling of basement membranes of adjacent tubuli are compared (arrowheads in G and H). Asterisks in D, E, and F in FSGS represent areas of glomerular sclerosis. Magnification, ×300.

Utrophin Localization in Glomeruli

In a preliminary investigation, we have tried to localize known intracellular binding partners of β-DG in glomeruli in unfixed cryostat sections of normal kidney by immunofluorescence. Utrophin was localized in a coarse granular pattern, outlining the contours of peripheral capillary loops (Figure 2), at least suggesting that utrophin is present within the glomerulus. Dystrophin was localized previously within the mesangial region (17), but not in peripheral capillary loops.

Figure 2.
Figure 2.

Utrophin is localized in cryostat sections of normal kidney by indirect immunofluorescence in glomerular capillary loops (CL) in a linear pattern (arrowheads) similar to that found for dystroglycans (12). Magnification, ×2400.

α- and β-DG Expression in Glomeruli

Immunoblotting with peptide-specific α- and β-DG antibodies on lysates of isolated human glomeruli and human skeletal muscle resulted in immunolabeling in both tissues of a 156-kD protein with the antibody specific for α-DG, and of 43 kD for β-DG (Figure 3).

Figure 3.
Figure 3.

Detection of α-dystroglycan (lanes A and C) and β-dystroglycan (lanes B and D) in isolated human glomeruli (lanes A and B) and in human skeletal muscle (lanes C and D). In both tissues, the antibodies used subsequently for immunocytochemistry specifically recognize α-dystroglycan with apparent molecular weight of 156 kD (lanes A and C), and β-dystroglycan, respectively, with molecular weight of 43 kD (lanes B and D).

α- and β-DG Localization at the Base of Foot Processes

Immunoelectron microscopy of normal human glomeruli on ultrathin cryosections or K4M Lowicryl-embedded material revealed specific, uniformly dense labeling exclusively on the podocyte's and foot processes' basal cell membrane that attaches to the GBM (Figures 4 and 6). The localization of α- and β-DG were identical, however, immunogold labeling intensity obtained with antibodies to α-DG were consistently stronger than with β-DG in K4M sections (Figures 5 and 7). No labeling was obtained on the cell membranes of endothelial cells, and few gold particles were localized to mesangial cell membranes. β1-Integrin was found on the podocyte's basal membrane domains, as well as on endothelial cells, as described (5).

Figure 4.
Figure 4.

Localization of α-dystroglycan in normal human kidney by immunogold labeling on ultrathin frozen sections. α-Dystroglycan is distributed in high density exclusively on the base of the foot processes (arrowheads in A) in an evenly dispersed pattern that is particularly well-recognized in grazing sections (D). Endothelial cells are not labeled. (B) In this ultrathin frozen section, the podocyte was mechanically removed, leaving intact the GBM and the endothelium (E). There is dense specific labeling for α-dystroglycan in the lamina rara externa, indicating that α-dystroglycan is firmly bound there and ripped out of the podocyte cell membrane by the cutting process. (C) Basal portion of a proximal tubule showing specific labeling on the basal cell membrane (arrowheads) toward the basement membrane (BM). Magnification, ×45,000.

Figure 6.
Figure 6.

Localization of β-dystroglycan in normal human glomeruli in ultrathin frozen sections. β-Dystroglycan is specifically localized in the cell membrane domain at the base of the foot processes (arrowheads), but not on the endothelium (E). Magnification, ×45,000.

Figure 5.
Figure 5.

Localization of α-dystroglycan in normal human kidney by immunogold labeling on Lowicryl-K4M sections. In this grazing section, the high density of α-dystroglycan on the basal membrane domains of podocytes is apparent. US, urinary space; E, endothelium; P, podocyte. Magnification, ×25,000.

Figure 7.
Figure 7.

Representative areas of labeling for α-dystroglycan in Lowicryl-K4M sections of normal kidney (A), segmental focal glomerulosclerosis (B), and MCN (C). Specific labeling of the basal cell membrane domains of podocytes is very dense (A). In segmental focal glomerulosclerosis (B), α-dystroglycan is concentrated in large patches (arrowheads), with large intervening “empty” domains. Occasionally, gold particles are also found within cytoplasmic vesicles in podocytes (inset). In contrast to A and B, the number of gold particles (arrowheads) is extremely reduced in MCN (C). US, urinary space; E, endothelium. Magnification, ×45,000.

Firm α-DG Adherence to the GBM

Occasionally, the podocytes were mechanically removed in ultrathin cryostat sections, leaving behind an intact GBM and endothelium. In these regions, dense specific immunogold labeling was observed for α-DG (Figure 4B), while gold particles indicating β-DG were detected only sporadically (data not shown).

Reduced Expression of Glomerular DG in MCN But Not in FSGS

When paraffin sections of renal biopsies with normal glomeruli (n = 4) and from patients with MCN (n = 16) were immunostained in parallel with anti-α- or β-DG antibodies, the majority of MCN glomeruli showed a much lower signal than normal glomeruli (Figure 1, G and H, Table 1). This difference became particularly apparent when the labeling density of glomeruli was compared to tubular basement membranes within the same section. By contrast, no gross difference in glomerular labeling intensity was observed in sections of 14 cases of FSGS (Figure 1, D and E).

To judge more objectively the expression of the DG than by light microscopic immunohistochemistry, we used quantitative immunogold electron microscopy (15). Renal biopsies of three normal kidneys and three cases of MCN and FSGS each were embedded in K4M Lowicryl (Figures 7 and 8). K4M sections were used for quantification of gold particles because they permitted the evaluation of large, continuous, and uniformly immunolabeled segments of glomeruli. Ultrathin sections were processed in parallel for immunogold surface labeling to minimize technical inconsistencies. The major result was that in MGN the density of gold particles at the base of the foot processes was significantly reduced to 25% for α-DG and >50% for β-DG when compared with controls (100%). By contrast, no difference in labeling intensity was observed in FSGS (n = 8) (Figure 9, Table 2), however, clustering of DG in basal podocyte membranes was observed, especially with anti-α-DG antibodies that labeled K4M sections more intensely than antibodies to β-DG (Figure 7B). The density of β1-integrin was identical in normal glomeruli and in MCN and FSGS (Figure 1, F and I).

Figure 8.
Figure 8.

Representative areas of labeling for β-dystroglycan in ultrathin frozen sections of normal kidney (A), segmental focal glomerulosclerosis (B), and MCN (C). The density of labeling is similar in A and B, but it is reduced in C. US, urinary space; E, endothelium; mvb, multivesicular body. Magnification, ×60,000.

Figure 9.
Figure 9.

Comparison by quantitative immunoelectron microscopy of the densities of α- and β-dystroglycan, and β1-integrin in basal cell membrane domain of podocyte foot processes in normal kidneys, MCN, and FSGS. This quantification substantiates the impression obtained by light microscopic immunocytochemistry (Figure 1) that α-dystroglycan is significantly reduced in MCN approximately to 25%, and β-dystroglycan to 50% of controls. By contrast, there is no significant reduction in FSGS. The expression of β1-integrin remains constant in all conditions. The number of gold particles per micrometer of cell membrane was determined on micrographs from K4M Lowicryl-embedded material, processed for indirect immunogold localization using two glomeruli from three patients in each condition. The density of gold particles in healthy control subjects was set at 100%, and that found in pathologic conditions was expressed as a fraction therefrom. Bars are SD. *P < 0.05.

Restoration of Glomerular DG in MCN by Steroid Treatment

Biopsies of four patients (three children, one adult) with MCN before and after clinically successful steroid therapy were immunolabeled with α-DG antibodies to indicate the DG complex. This was warranted because α- and β-DG were always expressed concomitantly (Figure 1). In all cases, the relative intensity of the glomerular histochemical reaction was very low before steroid treatment, and returned to normal levels after therapy, along with the restoration of normal foot processes (Table 2).

Discussion

MCN and FSGS are considered “podocyte diseases,” mainly because their principal pathologic feature is extensive flattening of foot processes, accompanied by nephrotic-range proteinuria (1,2,13). Both diseases may be related to each other (18), and they presumably represent a common pathway of different pathologic injuries to podocytes. FSGS is clinically characterized by progression and steroid resistance, whereas MCN is steroid-sensitive and disappears in most cases with adolescence. The severe derangement of podocyte foot processes raised the possibility that the interaction of extracellular matrix proteins via transmembrane connectors to the cytoskeleton could be defective, and thus mapping of podocyte adhesion proteins is of potential interest. The current inventory comprises α3 β1-integrin (5,6) and a heparan sulfate proteoglycan of the syndecan family (7). Here we have localized α- and β-DG to foot processes, and provided evidence for its faulty expression in MGN that is reversed by steroid treatment.

Among the established transmembrane linkers of the cytoskeleton to extracellular matrix, the DG complex is particularly interesting, because its sarcolemmal expression is dramatically reduced in several forms of muscular dystrophies (10,11). DG consists of two polypeptide chains, designated α- and β-DG, that are synthesized as single precursor and posttranslationally processed and cleaved to produce the transmembrane 43-kD β and the extracellular 156-kD α subunits. The α subunit is noncovalently bound to the ectodomain of the β subunit, and carries several O-linked, sialomucin-like carbohydrate side chains (19) that provide neuraminidase-sensitive binding sites for laminin G subunits that are also present in the GBM proteoglycans agrin and perlecan (20,21,22). The main intracellular binding partners of β-DG are dystrophin and its homologue utrophin that directly interact with actin (23). Although dystrophin is restricted to myocytes and in kidney to collecting tubules and the glomerular mesangium (17), utrophin and short forms of dystrophin are widely expressed in nonmuscle cells, including podocytes (Figure 2) (24,25). Thus, podocytes are endowed with a set of components of a transmembrane DG complex that includes utrophin, α- and β-DG, and laminin and proteoglycans in the GBM.

Besides providing cellular anchorage to the extracellular matrix, DG complexes profoundly influence the organization of basement membranes by orchestrating the positions of matrix proteins (26). For example, genetic “knockout” of DG results in a lethal phenotype that is caused by insufficient organization of Reichert's membrane (27). Reduced surface expression of the DG complex on cultured muscle cells by RNA antisense constructs causes failure of myocytes to organize an orderly basement membrane (26). Presumably for the same reason, addition to culture media of a monoclonal, ligand-blocking anti-α-DG antibody inhibited formation of glomeruli in an in vitro renal organogenesis system (28). Spatial positioning of DG within muscle cell membranes may be influenced by the cytoskeleton (29). Thus, the final organization of mature basement membranes is presumably a result of both spontaneous matrix protein assembly (4) and precisely controlled, nonrandom distribution by actin-guided DG complexes on cell membranes (26,29). Taken together with the findings that DG is exclusively localized to the basal cell membrane domains of podocytes and firmly adheres to the lamina rara externa of the GBM, the intriguing possibility exists that podocyte-controlled, actin-mediated, nonrandom positioning of DG complexes actively controls the arrangement of GBM matrix proteins, and thus influences the permeability of this prime glomerular filter barrier. The “division of labor” of podocyte adhesion between the DG complex and β1-integrin is not clear.

A major finding of this study was the precisely targeted localization of α- and β-DG to the basal cell membrane of foot processes. This “sole” of foot processes is a highly specialized domain that contains, besides integrin and DG, the membrane mucoprotein podoplanin (15), and on its edges the slit diaphragm-associated proteins p51 (30) and nephrin (31), all of which were implicated in triggering foot process flattening (32). The DG complex is known to support the formation of large, two-dimensional membrane protein complexes such as ion channels that are recruited by the PDZ domains of β-DG-linked utrophin (33). The basal cell membrane of foot processes is exquisitely rich in cholesterol (34), and it is possible that it contains “rafts” of membrane proteins (35) with reduced lateral membrane mobility and physical and functional coupling. DG and utrophin would be good candidates for the organization of rafts in a podocyte-governed, cytoskeleton-dependent manner, similar to their role in the assembly of neuromuscular synapses (36).

Is the expression of the podocyte's DG complex changed in glomerular diseases? Experimental animal models for flattening of foot processes are complex and may involve pathogenic mechanisms different from human diseases. Therefore, we have examined here the expression and distribution of DG directly in human renal biopsies from patients with MCN and FSGS. We have focused on these diseases because podocyte flattening appears to be the primary cause of the functional glomerular abnormalities. An obvious disadvantage was the restriction to archival biopsy material that permits immunohistochemical analysis only, because not enough glomerular material for RNA extraction was recovered by microdissection. With this limitation, we have used here carefully calibrated light microscopic immunocytochemistry and quantitative immunogold electron microscopy to determine the localization and density of DG on podocyte membranes.

In MCN, the density of expression of α-DG was significantly reduced to 25% of controls, and that of β-DG to approximately 50%. Because immunogold labeling for α-DG was more intense than that of β-DG, the values obtained for the former may reflect the situation more accurately. The expression of β1-integrin was not influenced at all (Figure 1). Interestingly, steroid treatment of MCN patients apparently restored the expression of DG, along with the reformation of foot processes. This is consistent with the finding that the surface expression of the DG complex was upregulated by steroids in vitro in cultured muscle cells (37,38). Thus, it is possible that in MCN restoration of podocyte shape and glomerular filtration function by steroid therapy may involve upregulation of DG expression. It remains to be determined whether utrophin is altered in MCN.

The significance of apparently normal density of DG in FSGS is unclear, and it is possible that DG is irrelevant in the pathogenesis of FSGS. However, clustering of α-DG within the podocyte's basal cell membrane domains could indicate some alterations of the DG complex that could be incapacitated by chemical modification, e.g., by local overproduction of reactive oxygen species as found in models of FSGS, such as mice with inactivated Mpv17 gene (39).

Reduced expression or partial disruption of the podocyte DG complex in MCN raises the question why patients with muscular dystrophies fail to develop podocyte damage and proteinuria. In skeletal muscle, DG interacts with dystrophin and also with the sarcoglycan (SG) protein-complex, consisting of four transmembrane subunits (10,11). Dystrophies develop when defects in any DG-binding proteins occur, while mutations in α- or β-DG apparently result in a lethal phenotype (27). Preliminary evidence indicates that neither dystrophin nor any component of the SG complex are present in podocytes (unpublished observations), and this could explain why the podocyte's DG complex is not affected in muscular dystrophies.

In conclusion, DG was localized to the basal cell membrane domain of foot processes, where it presumably forms a functional link between the podocyte's cytoskeleton and GBM matrix proteins such as agrin (21), and specific sites on laminin (40). Although both MCN and FSGS are characterized by extensive flattening of foot processes, they differ in the expression of DG, suggesting different, potentially pathogenic mechanisms of podocyte adhesion and foot process deformation.

Acknowledgments

Acknowledgments

This work was supported by the Sonderforschungsbereiche 05, Project 007 (to Dr Kerjaschki), and 06, Project F613 (to Dr. Bittner) from the Austrian Fonds zur Förderung der Wissenschaftlichen Forschung, and European Community Concerted Action Contract No. BMH4-98-3631 (to Dr Kerjaschki).

Footnotes

  • American Society of Nephrology

References

  1. ↵
    Olson JL: The nephrotic syndrome. In: Pathology of the Kidney, 4th Ed., edited by Heptinstall RH, Boston, Little Brown & Co., 1992, pp 779-869
  2. ↵
    Farquhar MG, Vernier RL, Good RA: Study of familial nephrosis. II. Glomerular changes observed with the electron microscope. Am J Pathol 33: 791-817,1957
  3. ↵
    Farquhar MG, Wissig SL, Palade GE: Glomerular permeability. I. Ferritin transfer across the normal glomerular capillary wall. J Exp Med 113: 47-59,1961
    OpenUrlAbstract
  4. ↵
    Timpl R, Brown JC: Supramolecular assembly of basement membranes.BioEssays 18:123 -132, 1996
    OpenUrlCrossRefPubMed
  5. ↵
    Kerjaschki D, Ojha PP, Susani M, Horvat R, Binder S, Hovorka A, Hillemanns P, Pytela R: A β1-integrin receptor for fibronectin in human glomeruli. Am J Pathol 134:481 -489, 1989
    OpenUrlPubMed
  6. ↵
    Adler S: Characterization of glomerular epithelial cell matrix receptors. Am J Pathol 141:571 -578, 1992
    OpenUrlPubMed
  7. ↵
    Woods A, Couchman JR: Signaling from the matrix to the cytoskeleton: Role of cell surface proteoglycans in matrix assembly.Kidney Int 49:S64 -S67, 1996
    OpenUrl
  8. ↵
    Kemeny E, Mihatsch MJ, Durmuller U, Gudat F: Podocytes loose their adhesive phenotype in focal segmental glomerulosclerosis. Clin Nephrol 43: 71-83,1995
    OpenUrlPubMed
  9. ↵
    Kreidberg JA, Donovan MJ, Goldstin SL, Rennke H, Shepherd K, Jones RC, Jaenisch R: α3 β1 integrin has a crucial role in kidney and lung organogenesis. Development122 : 3537-3547,1996
    OpenUrlAbstract
  10. ↵
    Hemler ME: Dystroglycan versatility. Cell97 : 543-546,1999
    OpenUrlCrossRefPubMed
  11. ↵
    Durbeej M, Henry MD, Campbell KP: Dystroglycan in development and disease. Curr Opin Cell Biol 10:594 -601, 1998
    OpenUrlCrossRefPubMed
  12. ↵
    Durbeej M, Henry MD, Ferletta M, Campbell KP, Ekblom P: Distribution of dystroglycan in normal adult mouse tissues. J Histochem Cytochem 46: 449-457,1998
    OpenUrlCrossRefPubMed
  13. ↵
    Grishman E, Churg J: Glomerular sclerosis in nephrotic patients: An electron microscopic study of podocytes. Kidney Int7 : 111-122,1975
    OpenUrlCrossRefPubMed
  14. ↵
    Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as specific marker for lymphatic endothelium.Am J Pathol 154:385 -394, 1999
    OpenUrlCrossRefPubMed
  15. ↵
    Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D: Podoplanin, a novel 43-kD membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis.Am J Pathol 1511:1141 -1152, 1997
    OpenUrl
  16. ↵
    Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D: Endothelial cell membranes contain podocalyxin, the major sialoprotein of glomerular epithelial cell. J Cell Biol102 : 484-491,1986
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Lidov HGW, Kunkel LM: Dystrophin and Dp140 in the adult rodent kidney. Lab Invest 78:1534 -1551, 1998
    OpenUrl
  18. ↵
    Fogo A, Hawkins EP, Berry PL, Glick AD, Chang ML, MacDonell RC Jr, Ichikawa I: Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 38: 115-121,1990
    OpenUrlCrossRefPubMed
  19. ↵
    Chiba A, Matsumara K, Yamada H, Inazu T, Shimizy T, Kusunoki S, Kanazawa I, Kobata A, Endo T: Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve α-dystroglycan. J Biol Chem 272:2156 -2162, 1997
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Talts JF, Zeynep A, Göhring W, Brancaccio A, Timpl R: Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins. EMBO J18 : 863-870,1999
    OpenUrlAbstract
  21. ↵
    Gesemann MM, Brancaccio A, Schumacher B, Ruegg M: Agrin is a high-affinity binding protein of dystroglycan in non-muscle tissue. J Biol Chem 273:600 -605, 1998
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Raats ICJ, Bakker MAH, Hoch W, Tamboer WPM, Groffen AJA, van den Heuvel LPWJ, Berden JHM, van den Born J: Differential expression of agrin in renal basement membranes as revealed by domain specific antibodies. J Biol Chem 273:17832 -17838, 1998
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Schmitz F, Holbach M, Drenckhahn D: Colocalization of retinal dystrophin and actin in postsynaptic dendrites of rod and cone photoreceptor synapses. Histochemistry 100:473 -479, 1993
    OpenUrlCrossRefPubMed
  24. ↵
    Kramarcy NR, Vidal A, Froehner SC, Sealock R: Association of utrophin and multiple dystrophin short forms with the mammalian M(r) 58,000 dystrophin associated protein (syntrophin). J Biol Chem69 : 870-876,1994
    OpenUrl
  25. ↵
    Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, Knight J, Kendrick-Jones J, Suthers GK, Love DR: Primary structure of a dystrophin related protein. Nature 360:591 -593, 1992
    OpenUrlCrossRefPubMed
  26. ↵
    Montanarro F, Lindenbaum M, Carbonetto S: α-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability. J Cell Biol 145:1325 -1340, 1999
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Williamson RA, Henry MD, Daniels KJ, Hrstka RF, Lee JC, Sunada Y, Ibraghimov-Beskrovnaya O, Campbell KP: Dystroglycan is essential for early embryonic development: Disruption of Reichert's membrane in Dag1-null mice.Hum Mol Gen 6:831 -841, 1997
    OpenUrlCrossRefPubMed
  28. ↵
    Durbeej M, Larsso E, Ibraghimov-Beskrovnaya, Roberd SL, Campbell KP, Ekblom P: Non-muscle α-dystroglycan is involved in epithelial development. J Cell Biol 130:79 -91, 1995
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Colognato H, Winkelmann DA, Yurchenko PD: Laminin polymerization induces a receptor-cytoskeleton network. J Cell Biol154 : 619-631,1999
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Orikasa M, Matsui K, Oite T, Shimizu F: Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol 141: 807-814,1988
    OpenUrlAbstract
  31. ↵
    Lenkkeri U, Mannikko M, McCready P, Lamberdin J, Gribouval O, Niaudet P, Antignac C, Kashtan CE, Holmberg C, Olsen A, Kestila M, Tryggvason K: Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations. Am J Hum Genet64 : 51-61,1999
    OpenUrlCrossRefPubMed
  32. ↵
    Matsui K, Breiteneder-Geleff S, Kerjaschki D: Epitope-specific antibodies to the 43 kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol9 : 2013-2026,1998
    OpenUrlAbstract
  33. ↵
    Kachinsky AM, Froehner SC, Milgram SL: A PDZ-containing scaffold related to the dystrophin complex at the basolateral membrane of epithelial cells. J Cell Biol 145:391 -402, 1999
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Orci L, Brown D, Amherdt A, Perrelet A: Distribution of intramembrane particles and filipin-sterol complexes in plasma membrane of kidney. I. Corpuscle of Malpighi. Lab Invest46 : 545-553,1982
    OpenUrlPubMed
  35. ↵
    Simons K, Ikonen E: Functional rafts in cell membranes.Nature 387:569 -572, 1997
    OpenUrlCrossRefPubMed
  36. ↵
    Peng HB, Xie H, Rossi SG, Rotundo RL: Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan.J Cell Biol 145:911 -921, 1999
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Pasquini F, Guerin C, Blake D, Davies K, Karpati G, Holland P: The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscul Disord 5: 105-114,1995
    OpenUrlCrossRefPubMed
  38. ↵
    Passaquin AC, Metzinger L, Leger JJ, Warter JM, Poindron P: Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse. J Neurosci Res35 : 363-372,1993
    OpenUrlCrossRefPubMed
  39. ↵
    Binder CJ, Weiher H, Exner M, Kerjaschki D: Glomerular overproduction of oxygen radicals in Mpv17 gene inactivated mice causes podocyte foot process flattening and proteinuria. Am J Pathol154 : 1067-1075,1999
    OpenUrlCrossRefPubMed
  40. ↵
    Abrahamson DR, Irwin MH, St. John PL, Perry EW, Accavitti MA, Heck LW, Couchman JR: Selective immunoreactivities of kidney basement membranes to monoclonal antibodies against laminin: Localization of the end of the long arm and the short arms to discrete microdomains. J Cell Biol109 : 3477-3491,1989
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
Glomerular Expression of Dystroglycans Is Reduced in Minimal Change Nephrosis But Not in Focal Segmental Glomerulosclerosis
HEINRICH M. REGELE, EDITH FILLIPOVIC, BRIGITTE LANGER, HELGA POCZEWKI, ILSE KRAXBERGER, REGINALD E. BITTNER, DONTSCHO KERJASCHKI
JASN Mar 2000, 11 (3) 403-412;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

More in this TOC Section

Cited By...

Similar Articles

Related Articles

  • No related articles found.